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ABSTRACT 
Metronomic chemotherapy (MCT), the chronic administration, at regular intervals, of 
low doses of chemotherapeutic drugs, without extended rest periods, allows chronic 
treatment with therapeutic efficacy and low toxicity. Our pre-clinical results suggested 
that combined MCT with cyclophosphamide (CY) and celecoxib (CEL) could inhibit 
breast cancer growth. The aim of this study was to determine the toxicity, safety and 
efficacy of the oral chronic administration of CY 50 mg p.o. daily, plus CEL 400 mg 
(200 mg p.o. bid) in advanced breast cancer patients (ABCP). The therapeutic response 
consisted in stable disease in a high proportion of patients and one partial response. The 
overall clinical benefit rate obtained was 66.7%. Toxicity was low. Evaluation of 
quality of life showed no changes during the response period. MCT with CY + Cel is 
safe and shows therapeutic effect in ABCP.  
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INTRODUCTION 
Breast cancer is the most common cancer and is the second leading cause of cancer 
death in American women, exceeded only by lung cancer [1]. In Argentine during 2008, 
there were 104.859 new cases of malignant tumors, being breast cancer the malignant 
illness with higher incidence in women (74/100000 women) [2]. 
Conventional cancer therapies (surgery, radiotherapy, chemotherapy) seem to have 
reached an efficacy therapeutic plateau with relative toxicity and detriment in the 
quality of life. Those characteristics accounts for increased costs in public health due 
to the need of implementing compensatory treatments and hospital admissions. 
A turning point in cancer chemotherapy can be placed in the year 2000, when Fidler and 
Ellis stated, “Cancer is a chronic disease and should be treated like other chronic 
diseases” [3]. In agreement with this concept, several groups, including ours, began to 
study a new modality of drug administration that Douglas Hanahan named “metronomic 
therapy” [4]. It consists of the administration of chronic, equally spaced and, generally, 
low doses of chemotherapeutic drugs without extended rest periods, that allows chronic 
treatment with therapeutic efficacy and low toxicity.  
Browder et al demonstrated the antiangiogenic effect of Cy using a low dose schedule; 
they also found that this effect was lost when using high doses and standard schedules 
due to the re-growth of tumor vasculature [5]. At variance with what it is observed when 
using standard chemotherapy schemes, they showed that metronomic chemotherapy 
(MCT) avoided drug resistance, a fact that may be attributed to the high genetic stability 
of the endothelial cell, the main target of MCT, less prone to develop drug resistance 
[6]. Similar results were also found by Klement et al [7]. Nevertheless, in a pre-clinical 
study, it was demonstrated resistance to MCT, although due to different mechanisms 
than those involved in resistance to drugs administered in the maximum tolerated dose 
(MTD) [8]. 
Tumor angiogenesis is a tumor micro-environmental process that promotes tumor cell 
survival and growth, invasion and metastasis [9]. Hence, antiangiogenic therapies would 
serve as antitumor ones. 
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Several mechanisms account for the anti-angiogenic effect of MCT observed in vivo. 
These include, selective inhibition of proliferation and/or induction of apoptosis of 
activated endothelial cells, selective inhibition of endothelial cell migration, increase in 
the expression level of the endogenous angiogenesis inhibitor thrombospondin-1 (TSP-
1) and sustained decrease in levels and viability of bone marrow-derived endothelial 
progenitor cells [10]. However, the inhibition of angiogenesis would not be the 
exclusive mechanism of action of MCT since certain drugs, like Cy, might contribute to 
the efficacy of the treatment through the stimulation of the immune response [10-12] 
Cyclophosphamide (Cy), an alkylating drug that exerts a toxic effect on proliferating 
cells, is one of the most used drugs in cancer chemotherapy being one of the earliest 
cytotoxic drugs used in MCT [5]. 
Cyclooxygenase 2 (COX-2) is a prostaglandin synthase enzyme that has been 
implicated in multiple stages throughout the tumorigenic process [13],  and that is over-
expressed in a variety of malignancies including breast cancer, at variance with COX-1, 
which is constitutively expressed in normal tissues. Recently, elevated COX-2 
expression in breast cancer has been also associated with the presence of distant 
metastases [14]. Celecoxib (Cel) is a selective inhibitor of COX-2 that has shown 
antiangiogenic [15] and antiproliferative [16] properties in breast cancer cell lines. 
The antitumor and antimetastatic properties of MCT with Cy as a mono-therapy [17], or 
in combination with Cel [18], were demonstrated in our pre-clinical tumor-models. The 
promising results obtained, in terms of therapeutic efficacy, good tolerability and low 
toxicity profile together with previous clinical experience by others setting the 
metronomic dose of Cy [19, 20] prompted us to conduct a phase I/II trial employing 
metronomic administration of Cy combined with Cel for the treatment of metastatic 
breast cancer (MBC) patients progressing after standard chemotherapy.  
In addition, we evaluated several biomarkers of angiogenesis including serum 
concentration of VEGF and TSP-1, and circulating (CECs) and progenitor (CEPs) 
endothelial cells, in an attempt to define their ability to predict response to the therapy.
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PATIENTS AND METHODS 
Eligibility 
Recruited patients were required to have histologically confirmed advanced breast 
cancer progressing after 3, and no more than 4, chemotherapy schemes. Other inclusion 
criteria were: age between 18 and 80 years; adequate bone marrow, renal and liver 
function, normal calcemia, at least one lesion according to RECIST criteria and more 
than 3 months of life expectancy. It was mandatory that all patients must be recovered 
from any prior chemotherapy, radiotherapy, or surgery before their inclusion. Each 
patient included in this study gave her written informed consent. This study was 
authorized by the School of Medicine Bioethics Committee and by A.N.M.A.T. 
(Argentine Regulatory Agency). 
 
Treatment and Evaluation 
All patients received Cy 50 mg p.o. daily, plus Cel 400 mg (200 mg p.o. bid).  
Baseline evaluation included clinical examination, chest X-ray, liver ultrasound or CT 
scan, and complete biochemical and hematologic tests. Patients were evaluated by 
physical examination and hematologic tests every 14 days during the first 6 months and 
every 28 days thereafter.  
Clinical response and toxicity were evaluated every two months or earlier if it was 
necessary. Patients were followed until progression or death.  
In case of G (grade) II neutropenia or thrombocytopenia, the dose of Cy was reduced to 
50% (25 mg/day), while if reaching GIII toxicity it was reduced to 25% of original dose 
(12.5 mg/day). Treatment was discontinued until hematologic recovery in case of GIV 
toxicity.  
In case of nausea and vomiting, dyspepsia, or GIII abdominal pain, Cel was reduced to 
50% (200 mg/day). More than two dose reductions or any gastrointestinal bleed GII or 
more resulted in study discontinuation.  
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Evaluation of CECs and CEPs 
Quantification of CECs and CEPs by flow cytometry was carried out on peripheral 
blood collected in tubes with EDTA and then separated by Ficoll-Hypaque gradient. 
Samples were collected at baseline, at the first three visits, and every 2 months 
thereafter. A panel of monoclonal antibodies, including anti-CD45-FITC (BD 
Pharmingen,USA) to exclude hematopoietic cells, anti-CD31-ALEXA Fluor ® 488 (BD 
Pharmingen) and anti-CD133-PE (Miltenyi Biotec, Germany) were used to determine 
the percentages of CECs and CEPs, respectively. Samples were evaluated using a 
Coulter Epics XL Flow cytometer.  
VEGF and TSP-1 quantification 
Levels of VEGF and TSP-1 were evaluated by ELISA in serum samples collected at 
baseline, at the first three visits, and every 2 months thereafter, with VEGF Quantikine 
(R&D Systems) and TSP-1 Quantikine (R&D Systems) kits. Blood samples were 
allowed to clot for 2 h at room temperature. After centrifugation, the serum was 
removed and stored at -20°C until used. The ELISA method was performed in 
duplicates, according to the manufacturer instructions.  
 
Adverse events and quality of life 
Toxicity was evaluated according to the CTCAE (National Cancer Institute's Common 
Terminology Criteria for Adverse Events) version 3.0. Life quality was evaluated by 
ECOG scale (Eastern Cooperative Oncologic Group) and FACT-B (The Functional 
Assessment of Cancer Therapy Breast) questionnaires. Physical well-being (GP), 
Social/family well-being (GS), Functional well-being (GF), Emotional well-being (GE), 
and Additional concerns (AC) were analyzed at three time points: baseline (BL); middle 
(MT) and end of treatment (ET). 
Study End Points 
The primary end point was the overall clinical benefit (OCB), which was defined as 
complete response (CR), partial response (PR), or stable disease (SD) ≥8 weeks. Tumor 
assessments were performed every 2 months according to WHO standard criteria and 
response was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST). 
Safety and tolerability were determined on the basis of the presence and grade of 
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adverse events. Time to progression (TTP) was calculated from baseline to the ﬁrst 
documentation of progressive disease (PD) or related death if this occurred before PD. 
Patients with death unrelated to breast cancer or this treatment were censored in TTP 
analysis. Response Duration (RD) was calculated from date of ﬁrst documented 
response (ie, CR, PR or SD) until date of ﬁrst documented PD.  
Study design and statistical analysis 
For this nonrandomized phase I/II trial, sample size calculation was based on an optimal 
two-stage minimax design [21]. This approach was used to investigate whether the 
overall response rate is sufficient to proceed to phase III trials with a minimum number 
of patients. The sample size for the trial was determined as follows. The threshold 
response rate was defined at 5% and the expected response rate was set at 25%. This 
study was regarded to be adequate to recruit a total of 25 patients (15 in the first stage 
and an additional 10 in the second), assuming an alpha error of 0.05 and beta error of 
0.10 based on Simon two-stage Phase II design [22]. The decision to continue or not to 
the second stage is based on the response rate obtained in the first one. If any response 
is obtained in at least one patient, the second stage will be carried out.  
 
The results were statistically analyzed, depending on the variable distribution, using 
parametric or non-parametric tests. Friedman and Wilcoxon signed-rank tests were used 
to assess whether median scores of FACT-B items were significantly different from 
baseline. Differences in VEGF and TSP-1 levels were evaluated by linear regression 
test. Kaplan Meier analysis was used to evaluate duration of response. Data were 
analyzed using the STATA statistical software (version 6) [23]. 
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RESULTS 
Patient characteristics  
Fifteen patients were enrolled, thus concluding the first stage of the study, while the 
enrollment of patients continues until completion of the pre-established number of 25. 
Baseline characteristics of patients and tumors are depicted in Table 1. The median age 
was 61 years (range: 38-78). All patients were heavily pretreated, 7/15 and 8/15 
received 3 and 4 prior chemotherapy regimens, respectively. The most frequent 
metastases locations were liver and bone. 
Toxicity and adverse events 
The hematologic adverse events associated with the therapy were: Anemia G2 (n=4/15), 
leukopenia G1 (n=2/15) and G2 (n=2/15), neutropenia G1 (n=1/15) and G2 (n=2/15), 
thrombocytopenia GI (n=1/15). Those events were easily overcome with transitory 
reduction of Cy doses (Online Resource 1). Four patients over fifteen developed G1 
dyspepsia related to the treatment, a toxicity that did not affect compliance and reversed 
easily with the administration of omeprazole 20 mg v.o. daily. All the adverse events, 
whether related or not to the therapy are summarized in Table 2. 
There was no evidence of hepatic, renal or cardiac toxicities associated with the therapy. 
Minimal changes in liver enzymes (lactate dehydrogenase and alkaline phosphatase) 
were likely due to the underlying disease or related to disease progression. Ca 15-3 
concentrations increased at the time of disease progression, and those values, along with 
CT scan, were useful to identify patients who were unresponsive to therapy (Online 
Resource 2). 
Therapeutic response 
A partial response (PR) was observed in 1 patient (6.7%), which lasted 6 weeks. Stable 
disease (SD) was observed in 9/15 patients (60%). Median RD among patients with 
stable disease was 19.24 weeks (range: 4-73.6). The OCB obtained was 66.7% 
(PR=1/15 + SD=9/15). The median TTP was 14 weeks (range: 3.7-81.6) for responder 
patients. The evolution of the percentage of progression free survival is shown in Fig.1. 
Biomarkers  
The percentages of CECs and CEPs were assessed along the treatment a non-clear trend 
variation was observed in the percentages of CECs and CEPs. The same behavior was 
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obtained when patients were classified in responder (R) and non-responder (NR) for the 
percentages of CECs in R (Fig.2A), NR (Fig.2B) and of CEPs in R (Fig. 2C). 
Interestingly, NR patients showed a tendency to increase the values of CEPs (Fig. 2D) 
during their permanence in the study.  
Serum concentration of VEGF decreased as a function of time (P=0.004) (Fig. 3A). On 
the other hand, TSP-1 levels did not show significant modifications (Fig. 3B), even 
when they were classified in R and NR. 
Life quality 
FACT-B questionnaire 
During follow-up, when comparing the FACT-B items during response (from BL to 
MT), no significant differences were observed. When questionnaires corresponding to 
the end of treatment (ET) were included in the statistical analysis, the item AC showed a 
significant increase (P=0.008), while for GF the increase was marginally significant 
(P=0.055) (Online resource 3).   
ECOG evaluation 
In assessing the performance status by means of the ECOG scale, the value 
corresponding to the time of progression was not included. Four patients over 15 
(26.7%) were not evaluated since their permanence in the treatment was 8 weeks. The 
analysis showed no changes in the score in 1/11 (9%) patients, a worsened score in 4/11 
(36.4%) patients, a transitory and a permanent improved score in 2/11 (18.2%) and 4/11 
(36.4%) patients, respectively (Online Resource 4).  
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DISCUSSION 
Effective, noninvasive and low toxicity treatments for breast cancer represent a 
challenge for medical oncologists. For decades the pharmaceutical industry has been 
focused in developing antineoplastic agents with high cytotoxic effect on tumor cells. 
This effect is related to agent doses and is the main cause of anti-tumor efficacy; 
however it is also accompanied by toxicity and deterioration of quality of life.  
Angiogenesis represents a key process in carcinogenesis. Antiangiogenic drugs interfere 
in many common pathways shared in all neoplastic cells in an unspecific fashion [24]. 
The mechanism of action of MCT proposed by Folkman and Kerbel points to the tumor 
endothelial cells which, indirectly, destroy naive and resistant cancer cells by induction 
of hypoxia and nutrients deprivation. These mechanisms had been validated in pre-
clinical and clinical models. However, additional mechanisms of action may be 
involved like induction of tumor dormancy and immunomodulation [10, 12]. 
Based in our pre-clinical studies [18], we designed this trial to evaluate the safety, 
efficacy of MCT with Cy plus Cel in advanced breast cancer refractory to standard 
chemotherapy, along with the identification of possible biomarkers to predict response 
to therapy. 
The OCB obtained was 66.7% (PR=1/15 and SD=9/15). This result is very encouraging, 
considering the stage of the disease and the low possibility of obtaining a long term 
clinical benefit after 3 or 4 lines of chemotherapy. Interestingly, we obtained similar 
results to those achieved with standard regimens administered to metastatic breast 
cancer patients but avoiding toxicity. Accordingly, the use of gemcitabine and 
carboplatin plus iniparib yielded a 56% OCB rate [25], while the administration of 
capecitabine and vinorelbine in HER2-negative patients reached a OCB rate of 70% 
[26] and the combination of paclitaxel with gemcitabine resulted in a 80% OCB rate 
[27].   
In agreement to our findings, other promising results using MCT were obtained in 
patients with metastatic breast cancer treated with Cy plus Methotrexate (Mtx) [28], Cy 
plus Mtx and Thalidomide [29], Cy plus Mtx and Trastuzumab in Her2/neu+ patients 
[30]; besides, it was recently demonstrated that MCT with capecitabine displayed good 
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therapeutic activity in advanced breast cancer [31]. Also, in patients with colorectal 
cancer at high risk of recurrence, adjuvant postoperative MCT using Irinotecan plus 
Uracil and Tegafur improved overall survival rates [32]. Moreover, patients with 
advanced hormone refractory prostate cancer treated with a single standard dose of Cy 
followed by MCT with Cel and Dexamethasone showed biological activity and low 
toxicity profile [33].  On the other hand, OA Khan et al, in a large Phase II trial 
including heavily pretreated patients with different types of cancer (breast, 
gastrointestinal, melanoma, ovarian, prostate, renal) and treated with daily Cy, Cel and 
weekly Mtx found no toxicity, but also non-objective response, and short duration of 
SD  [34].  
We documented long term SD in 60% of the patients who showed median TTP and RD 
of 14 and 19.2 weeks, respectively. These results are similar to those found by Salem et 
al. [35], with a MRD of 4±0.84 months, and lower than the 6.8 months found by 
Colleoni et al. [28]. 
We found very low toxicity, being myelosuppression the most common event associated 
to Cy treatment. Interestingly, it was easily reverted by temporary dose reduction. 
Gastrointestinal toxicity was also minimal. Compared to other standard schemes of 
treatment [36], the side effects derived from the present treatment were minimal. 
Several authors have demonstrated, in pre-clinical models, the therapeutic effect of 
metronomic administration of Cy in combination with various antiangiogenic agents 
such as angiogenesis inhibitor TNP-470 [5], imatinib [37], the angiogenic peptide ABT-
510 [38], tirapazamine [39], cetuximab, anti-EGFR [40], 5-fluorouracil prodrug UFT 
[41], the angiogenesis inhibitor axitinib [42] and others, in the treatment of different 
types of tumors, including lung cancer and leukemia [5], pancreatic carcinoma [37], 
prostate [38], colon [39], and breast [41].  
One of the most important angiogenic molecules is VEGF, which stimulates adhesion, 
proliferation and survival of normal endothelial cells. While its expression is strictly 
regulated in normal tissue, the overexpression of VEGF has been observed in several 
tumor models, associated to abnormal blood vessels [6]. On the other hand, anti-
angiogenic factors like TSP-1 inhibiting proliferation, growth, motility and adhesion of 
tumor endothelial cells may be involved in the regulation of tumor angiogenesis [43]. 
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Also, the recruitment of hematopoietic cells and circulating endothelial progenitor cells 
(CEP) derived from bone marrow, are necessary for tumor angiogenesis 
[44]. The CEPs, which can be mobilized from the bone marrow by growth factors such 
as VEGF, cytokines or ischemia [45], would be a MCT cell target, as well [46]. 
In order to find possible markers of response to therapy, we evaluated serum levels of 
VEGF and TSP-1 and percentages of circulating CECs and CEPs. Serum VEGF showed 
a significant decrease over time, supporting the anti-angiogenic effect of the treatment. 
However, the limitations in the number of patients included so far preclude from 
assuring its usefulness as a marker of response. Different results were obtained in a 
Phase II study conducted with bevacizumab and metronomic oral dose of Cy in patients 
with recurrent ovarian tumors, in which no correlation was found between VEGF levels 
and response to treatment [47]. On the other hand, treatment with MCT with daily Cy, 
dalteparin and prednisone and twice-weekly dose of Mtx in patients with metastatic 
breast cancer, showed clinical activity, a non-significant decrease of VEGF, along with 
a significant increase in receptors sVEGFR-1 and sVEGFR-2 after two weeks of 
therapy [48], although a combination of Cy, Cel and Mtx showed negligible activity in 
advanced cancer and the analysis of several biomarkers (included VEGF) indicated 
minimal effects on endothelium [34]. 
Thrombospondin 1 is a potent and highly specific inhibitor of angiogenesis and it is 
considered a secondary mediator of the antiangiogenic effect of some MCT regimens 
[49]. However, MCT with Cy + Cel did not significantly modify, in our patients, TSP-1 
serum concentration. Moreover, those values did not correlate to disease progression or 
treatment response. Accordingly, several studies also failed to find such a correlation. In 
a trial of MCT with Cy + Cel and Dexamethasone in advanced hormone-refractory 
prostate cancer patients [33], the plasma TSP-1 level, while highly variable, increased 
during treatment in both, responsive and unresponsive patients. In another trial 
comparing metronomic versus MTD of cisplatin and docetaxel given i.v. in patients 
with lung cancer, no significant changes in VEGF, TSP1 and VEGFR1 levels were 
found in the group treated with MCT [50]. Recently it was shown a decrease in TSP-1 
levels in patients receiving metronomic Cy a change that did not correlate to clinical 
benefit [51] 
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The proportion of CEPs in NR patients showed a tendency to higher values during their 
time of permanence. Accordingly, a study in ovarian cancer patients showed that high 
circulating CEPs correlated with poor overall survival [52]. On the contrary, other 
studies in Hodgkin lymphoma [20] and breast cancer [19] patients, showed a decrease 
of CEPs and/or CECs, when treated with Cy plus Cel or Cy plus capecitabine and 
bevacizumab, respectively Our preliminary results, together with data from other 
reports, are yet scarce to consider the use of CEPs or CECs as biomarkers to identify 
patients who are candidates to antiangiogenic therapy, but may be useful to evaluate 
treatment response after its initiation.   
One common outcome when employing MTD regimens is a deterioration of life quality. 
On the contrary, what we have found so far is that quality of life, assessed by 
the FACT-B questionnaire, showed no changes during the response period. This is an 
interesting finding, considering the type of patients we are dealing with. When the 
questionnaire corresponding to the end of treatment was also included for the statistical 
analysis, the only item that showed a significant increase was AC. The increase of the 
additional concerns could be likely due to fear, frustration or to the knowledge of lack 
of additional curative treatments. Moreover, assessment of functional status using the 
ECOG scale showed that 70% of patients improved or did not change their condition. 
Such a result may be mainly attributed to stable disease, noninvasive drug 
administration, low toxicity of the treatment, anti-inflammatory effect of Cel and also, 
to a subjective factor from the patient. 
In conclusion, MCT combining Cy and Cel for treating advanced breast cancer showed 
very low toxicity and therapeutic response in a high proportion of patients. The decrease 
of serum VEGF confirmed the antiangiogenic nature of the drug combination and 
therapeutic schedule. There was no deterioration of the life quality in a high proportion 
of patients, a result that represents one of the most important rewards, considering their 
stage of disease progression at the beginning of the therapy.  
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FUTURE PERSPECTIVE 
The promising results obtained in the first stage of the trial warrants not only its 
prosecution to the second stage but also the design of new protocols targeting to patients 
in earlier stages of the disease, on its completion.  
EXECUTIVE SUMMARY 
Metronomic chemotherapy with cyclophosphamide plus celecoxib administered to 
advanced breast cancer patients yielded the following results: 
 The adverse events related to the therapy where few and mild (GI or GII), 
mainly hematologic and gastrointestinal. 
 The OCB obtained was 66.7% (PR=1/15 + SD=9/15). The median TTP and RD 
was 14 and 19.2 weeks. 
 Serum concentration of VEGF decreased significantly as a function of time. 
 CEPs showed a tendency to higher values during treatment in non-responder 
patients 
 When comparing the FACT-B items during response no significant differences 
were observed. 
 The performance status measured by the ECOG scale showed no modification or 
improvement in 7/11 (63.6%) of the responder patients.  
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Figure Legends 
Fig.1. Evolution of the percentage of progression free survival 
Fig.2. Individual variation of percentage of CECs (A and B) and CEPs (C and D) in 
responder (n=10) and non-responder (n=5) patients, respectively.  
Fig.3. Individual variations of VEGF (A) and TSP-1 (B) serum concentrations. The grey 
zones indicate the range of normal values. Linear regression analysis; A) r2=0.113; 
P=0.0042; B) r2=0.002; P=0.71.  
On-Line Resources  
Online Resource 1. Evolution of hematologic parameters 
Online Resource 2. Evolution of serologic parameters 
Online Resource 3. FACT B questionnaire 
Online Resource 4. Evolution of Performance status 
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Online Resource 1 
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Online Resource 1. Evolution of hematologic parameters. The grey zones indicate the range of normal 
values. 
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Online Resource 2 
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Online Resource 2. Evolution of serologic parameters. The grey zones indicate the range of normal 
values. Deviations from normality in values of the hepatic enzymes LDH and AP were caused by baseline 
disease. High levels of CP were present before the start of the treatment, and were not associated to the 
therapy. CA 15-3 antigen increased at the time of progression. 
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Online Resource 3 
 
 
GP: Physical well-being; GS: Social/family well-being; GF: Functional well-being; GE: Emotional well-
being; AC: Additional concerns. 
BL: Baseline; MT: Middle of treatment; ET: End of treatment. 
MS= Missing data. 
+P (DR) = P value (Wilcoxon signed-rank test) during response (BL-MT); *P (DT) = P value (Friedman 
Test) during all treatment (BL-MT-ET). 
 
 
 
 
 
 
 
Quality of life during the follow-up, evaluated by the FACT-B questionnaire. 
Patient 
GP GS GF GE AC 
BL MT ET 
P 
(DR)+ 
P (DT)* BL MT ET 
P 
(DR) 
P (DT) BL MT ET 
P 
(DR) 
P (DT) BL MT ET 
P 
(DR) 
P (DT) BL MT ET 
P 
(DR) 
P (DT) 
1 5 10 22 
0.271 0.651 
5 4 0 
0.765 0.622 
22 19 22 
0.247 0.055 
13 7 16 
0.665 0.144 
13 13 17 
0,432 0,008 
2 4 MS 7 3 MS 4 4 MS 7 10 MS 11 7 MS 9 
3 3 5 7 10 9 11 2 4 3 1 2 3 10 11 17 
4 6 11 11 3 4 4 4 14 5 2 9 7 11 22 15 
5 6 2 1 5 6 4 16 8 8 10 8 10 11 17 15 
6 7 3 11 5 0 8 13 8 15 11 8 9 9 6 17 
7 5 13 4 12 4 3 3 3 5 11 13 10 10 14 10 
8 15 8 12 3 3 7 4 4 5 8 8 10 9 10 12 
9 15 MS 11 7 MS 0 18 MS 13 20 MS 17 19 MS 22 
10 28 15 24 5 17 13 20 16 17 28 22 28 22 25 23 
11 8 10 10 5 9 6 7 14 16 14 12 16 9 11 17 
12 8 8 28 4 4 1 9 6 17 6 11 24 14 17 24 
13 5 1 7 0 0 0 4 1 16 3 0 15 12 14 22 
14 25 5 1 0 0 0 20 7 7 8 16 16 23 8 24 
15 28 14 5 0 3 0 7 6 5 19 12 15 23 5 6 
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Online Resource 4 
 
 ECOG Scale 
 Time (Weeks) 
Patient 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 
1 2 2 2 3 
            2 2 2 
              3 3 3 2 
             4 3 3 2 2 
            5 2 1 1 2 
            6 2 2 1 
 
1 1 1 1 1 
  
1 1 1 1 1 
7 3 3 2 2 2 3 
          8 1 1 2 
  
1 2 2 2 1 
      9 2 3 
              10 1 1 2 3 
            11 1 1 1 1 2 3 
          12 1 1 1 1 1 1 
  
2 3 
      13 2 1 1 1 2 2 2 
         14 2 3      
15 2 1 2 1 1            
 
Online Resource 4.Performance Status - ECOG Scale 
 
 
 
 
 
 
 
 
